gemcitabine has been researched along with bortezomib in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (42.37) | 29.6817 |
| 2010's | 30 (50.85) | 24.3611 |
| 2020's | 4 (6.78) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bold, RJ; McConkey, DJ; Virudachalam, S | 1 |
| Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S | 1 |
| Bar-Eli, M; Davis, DW; Dinney, CP; Kamat, AM; Karashima, T; Lashinger, L; McConkey, DJ; Millikan, R; Shen, Y | 1 |
| Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK | 1 |
| Reddy, KG | 1 |
| Callery, MP; Canete, JJ; Chandler, NM | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Kiselyov, A | 1 |
| Ann, DK; Boo, LM; Chen, Y; Chung, V; Liu, X; Nguyen, HV; Song, J; Yen, Y; Zhou, B; Zhu, L | 1 |
| Giaccone, G; Voortman, J | 1 |
| Laurie, SA; Licitra, L | 1 |
| Appleman, LJ; Clark, JW; Cusack, J; Eder, JP; Enzinger, PC; Fidias, P; Fishman, M; Kashala, O; Lynch, T; Ryan, DP; Supko, JG; Zhu, AX | 1 |
| Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J | 1 |
| Gao, SL; Shen, HW; Tang, ZY; Wu, YL | 1 |
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Bernstein, SH; Fisher, RI; Friedberg, JW; Jordan, CT; Kelly, J; Liesveld, J; Marquis, D; Mendler, JH; Rich, L; Rossi, RM; Voci, S | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Ceresa, C; Giaccone, G; Giovannetti, E; Honeywell, R; Laan, AC; Peters, GJ; Voortman, J | 1 |
| Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L | 1 |
| Chow, W; Cristea, M; Doroshow, JH; Frankel, P; Gaur, S; Koczywas, M; Lim, D; Luu, T; Margolin, K; Morgan, RJ; Somlo, G; Yen, Y | 1 |
| Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G | 1 |
| Barbarat, A; Houlgatte, R; Raharijaona, M; Rolland, D; Thieblemont, C | 1 |
| Bommakanti, SV; Dudek, AZ; Gada, PD; Khatri, A; Kirstein, MN | 1 |
| Farid, M; Koo, GC; Lim, ST; Loong, S; Quek, R; Tao, M; Tay, K; Yau, YW | 1 |
| Assouline, S; Buckstein, R; Chua, NS; Crump, M; Eisenhauer, E; Fernandez, LA; Gascoyne, RD; Klasa, RJ; Kouroukis, CT; Powers, J; Turner, R; Walsh, W | 1 |
| Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB | 1 |
| Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A | 1 |
| Duvic, M; Falchook, GS; Hong, DS; Kurzrock, R; Lim, J; Naing, A; Wheler, J | 1 |
| Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT | 1 |
| Cao, Q; Dudek, AZ; Wang, H | 1 |
| Downward, J; Hancock, DC; Howell, M; Kelly, G; Kuznetsov, H; Marani, M; Molina-Arcas, M; Saunders, B; Steckel, M; Warne, PH; Weigelt, B | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Colvin, J; Evens, AM; Gordon, LI; Helenowski, I; Kline, J; Larsen, A; Rosen, ST; Smith, SM; van Besien, KM; Winter, JN | 1 |
| Mangone, M; Marchi, E; O'Connor, OA; Zullo, K | 1 |
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
| Chien, W; Ding, LW; Garg, M; Gery, S; Kitajima, S; Koeffler, PH; Lee, KL; Leong, WZ; Lim, SL; Poellinger, L; Sun, H; Sun, QY; Takao, S; Tan, SZ; Tokatly, I; Torres-Fernandez, LA; Xiao, J | 1 |
| Uwagawa, T; Yanaga, K | 1 |
| Betticher, D; Egger, T; Keller, S; Mansouri Taleghani, B; Mueller, BU; Pabst, T; Rauch, D; Seipel, K | 1 |
| Duvic, M | 1 |
| Anastasia, A; Angelucci, E; Annechini, G; Balzarotti, M; Bonfichi, M; Botto, B; Brusamolino, E; Carella, AM; Congiu, A; Giordano, L; Gotti, M; Magagnoli, M; Massidda, S; Mazza, R; Merli, F; Murru, R; Re, A; Rodari, M; Russo, E; Salvi, F; Santoro, A; Spina, M; Stelitano, C; Vitolo, U; Zilioli, VR | 1 |
| Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Agelaki, S; Filippa, G; Georgoulias, V; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mala, A; Mavroudis, D; Moutsos, M; Syrigos, K; Vamvakas, L; Ziras, N | 1 |
| Alazraki, A; Carden, MA; Meany, H; Rapkin, LB; Smith, S; Yin, H | 1 |
| Hanazaki, K; Kitagwa, H; Munekage, M; Namikawa, T; Sugimura, K; Takezaki, Y | 1 |
| Choi, HG; Gupta, B; Jeong, JH; Kim, JO; Oh, KT; Pathak, S; Poudel, BK; Ramasamy, T; Thapa, RK; Yong, CS | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L | 1 |
| Hirabayashi, K; Kikuta, K; Kondo, T; Noguchi, R; Ono, T; Ozawa, I; Sei, A; Yoshimatsu, Y | 2 |
4 review(s) available for gemcitabine and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome | 2015 |
16 trial(s) available for gemcitabine and bortezomib
| Article | Year |
|---|---|
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2006 |
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2007 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Pyrazines | 2009 |
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Pyrazines | 2010 |
Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines | 2011 |
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Medical Oncology; Middle Aged; National Health Programs; Pyrazines; Recurrence; Societies, Medical | 2011 |
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Treatment Outcome; Young Adult | 2012 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Pralatrexate pharmacology and clinical development.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Depsipeptides; Disease-Free Survival; Drug Approval; Drug Synergism; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2016 |
A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2016 |
39 other study(ies) available for gemcitabine and bortezomib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2003 |
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Death; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured | 2004 |
Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Camptothecin; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Forecasting; Gemcitabine; Green Fluorescent Proteins; Humans; Image Enhancement; Irinotecan; Luminescent Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Pyrazines; Red Fluorescent Protein; Technology, Pharmaceutical; Treatment Outcome | 2005 |
SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; NF-kappa B; Oropharyngeal Neoplasms; Pyrazines; SUMO-1 Protein | 2006 |
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left | 2006 |
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib | 2007 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine | 2009 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult | 2010 |
Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cytarabine; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione S-Transferase pi; Humans; Lectins; Lymphoma, Mantle-Cell; Pyrazines | 2010 |
A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Outcome | 2011 |
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2011 |
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Colonic Neoplasms; Deoxycytidine; DNA Topoisomerases, Type I; GATA2 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mutation; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; RNA Interference; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Transcriptional Activation | 2012 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Naphthalenes; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA Splicing; Sulfonamides; Thiophenes; Toyocamycin; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2014 |
Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Polyneuropathies; Transplantation, Autologous; Treatment Outcome | 2016 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat | 2015 |
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
Topics: Adult; Antineoplastic Agents; Apoptosis; Bortezomib; Busulfan; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Membrane Potential, Mitochondrial; Middle Aged; Panobinostat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2016 |
Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Medullary; Child; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Paclitaxel | 2017 |
[Antitumor Effects of a Combined Treatment with Bortezomib and Gemcitabine in Bile Duct Cancer Cell Lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bortezomib; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; NF-kappa B; Signal Transduction | 2016 |
PEGylated thermosensitive lipid-coated hollow gold nanoshells for effective combinational chemo-photothermal therapy of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gemcitabine; Gold; Humans; Hydrophobic and Hydrophilic Interactions; Infrared Rays; Lipids; Nanoshells; Pancreatic Neoplasms; Phototherapy; Polyethylene Glycols; Temperature | 2017 |
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2017 |
Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Drug Tapering; Fibroma; Gemcitabine; Humans; Loss of Function Mutation; Male; Neoplasm Invasiveness; Neurofibromin 1; PTEN Phosphohydrolase; Topotecan | 2021 |
Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma.
Topics: Antineoplastic Agents; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Gemcitabine; Gene Deletion; Genes, Neoplasm; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Invasiveness | 2021 |